Literature DB >> 15503413

CTX-M beta-lactamase-producing Escherichia coli in long-term care facilities, France.

Najjiby Kassis-Chikhani, Sophie Vimont, Karine Asselat, Christophe Trivalle, Bérédia Minassian, Christian Sengelin, Valérie Gautier, Daniéle Mathieu, Elisabeth Dussaix, Guillaume Arlet.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15503413      PMCID: PMC3320274          DOI: 10.3201/eid1009.030969

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: In long-term care facilities, most endemic infections affect respiratory and urinary tracts, as well as skin and soft tissues (–). Infection and colonization by antimicrobial-resistant organisms, in particular those producing plasmid-mediated extended-spectrum β-lactamases (ESBL), are common in long-term care facilities (). Since 1984, ESBL-producing Enterobacteriaceae have spread among French hospitals; within Parisian public hospitals (Assistance Publique, Hôpitaux de Paris), ESBL-producing Escherichia coli is the most frequent species found, representing 49.5% of 220 Enterobacteriaceae isolated in 2002, mostly in urinary tract infections (). Among ESBL-producing Enterobacteriaceae, CTX-M–type β-lactamases confer a higher level of resistance to cefotaxime and ceftriaxone than to ceftazidime. CTX-M–producing strains are endemic in Latin America, Japan, and certain parts of Eastern Europe; in contrast, these strains are emerging in France, Western Europe, and the United States (). We report the first documented outbreak of CTX-M–producing E. coli infection in a long-term care facility in France. Our hospital is an 800-bed institution with 300 beds for long-term patients distributed among three units located in two buildings. The outbreak occurred in a 35-bed unit and involved 26 of 47 hospitalized patients from October 2001 to March 2003. This facility hosts patients for extended periods of time or permanently. The index case was identified in October 2001; the patient had a urinary tract infection attributable to an ESBL-producing E. coli, which showed resistance patterns not previously found in our hospital. Three new cases were detected within the following 2 months, and all patients had urinary tract infection with the same pattern of resistance. In January 2002, patients were screened for ESBL-producing strains by rectal swabbing and urine culture. The results showed E. coli with a high level of resistance to amoxicillin and ticarcillin (MIC > 128 µg/mL), partial restoration of susceptibility to these agents by addition of clavulanic acid (MIC = 16–32 µg/mL), and higher resistance to cefotaxime (MIC > 128 µg/mL) than to ceftazidime (MIC = 32–64 µg/mL.) A cephalosporin/co-amoxiclav synergy test was positive, which suggests a CTX-M ESBL. Strains were also resistant to ciprofloxacin (MIC 64 µg/mL) and gentamicin (MIC > 64 µg/mL) but remained susceptible to trimethoprim-sulfamethoxazole. Attempts to transfer resistance to β-lactams by conjugation to E. coli J53-2 with the 26 strains tested were unsuccessful. In contrast, transformants were obtained with plasmid DNA of the 19 strains tested by electroporation. The transformants' susceptibility pattern was similar to that of the donor strains, except for ciprofloxacin resistance. Analytical isoelectric focusing showed that all clinical strains and transformants had bands of β-lactamase activity with an alkaline pI of 7.6 and 5.4. Polymerase chain reaction (PCR) amplification of the 26 clinical isolates was positive for blaCTX-M and blaTEM (). The 26 strains of E. coli had the same profile by repetitive-element PCR and pulsed-field gel electrophoresis, while unrelated control strains had very different profiles. Sequencing in strains isolated from four of the patients identified a CTX-M-15 β-lactamase and a TEM-1 β-lactamase. The four strains were related to the phylogenetic group B2 and produced the iutA (ferric aerobactin receptor), YuA (Yersinia siderophore receptor), and fimH (type I fimbriae) virulence factors (). Incidence of colonization or infection by the culprit strain was 34.3% (12 of 35 patients) within the initial 4-month period and 55.3% (26 of 47 patients) over a 1-year period. Intensified hygienic procedures implemented in January 2002 contributed to a decrease in the number of cases in February only; since then, a regular increase of new cases extended the outbreak and caused problems with controlling it. All urinary tract infections were successfully treated with a 15-day course of trimethoprim-sulfamethoxazole; however, reinfection occurred in some. Neither incontinence (p = 0.35), dementia (p = 0.22), nor previous antibiotic treatment (amoxicillin, amoxicillin-clavulanic acid, extended-spectrum cephalosporins, and fluoroquinolones [p = 1.00, 0.30, 0.12, 0.52, respectively]) appeared to be risk factors for infection or colonization in our study, but the number of patients is too small to reach a conclusion. However, patients that were infected or colonized had greater functional impairment, especially incontinence and dementia. Nonambulatory status, decubitus ulcers, and feeding tubes were not risk factors for acquiring ESBL-producing E. coli in our study. The outbreak has not been controlled: 13 patients have persistent digestive-tract colonization. Difficulties encountered in controlling such outbreaks may be explained by several factors. Patients cannot be easily isolated in long-term care facilities. Strict isolation and limitation of activity and mobility cannot always be applied because of their impact on social activities.
  7 in total

Review 1.  Extraintestinal pathogenic Escherichia coli: "the other bad E coli".

Authors:  James R Johnson; Thomas A Russo
Journal:  J Lab Clin Med       Date:  2002-03

2.  Infection control in long-term care facilities.

Authors:  L E Nicolle
Journal:  Clin Infect Dis       Date:  2000-09-21       Impact factor: 9.079

Review 3.  Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes.

Authors:  R Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

Review 4.  Infections and antibiotic resistance in nursing homes.

Authors:  L E Nicolle; L J Strausbaugh; R A Garibaldi
Journal:  Clin Microbiol Rev       Date:  1996-01       Impact factor: 26.132

5.  Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes.

Authors:  J Wiener; J P Quinn; P A Bradford; R V Goering; C Nathan; K Bush; R A Weinstein
Journal:  JAMA       Date:  1999-02-10       Impact factor: 56.272

Review 6.  Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention.

Authors:  R R Muder
Journal:  Am J Med       Date:  1998-10       Impact factor: 4.965

7.  Dissemination of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Paris, France.

Authors:  C Eckert; V Gautier; M Saladin-Allard; N Hidri; C Verdet; Z Ould-Hocine; G Barnaud; F Delisle; A Rossier; T Lambert; A Philippon; G Arlet
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

  7 in total
  9 in total

1.  Clonal dissemination of a CTX-M-15 beta-lactamase-producing Escherichia coli strain in the Paris area, Tunis, and Bangui.

Authors:  M Lavollay; K Mamlouk; T Frank; A Akpabie; B Burghoffer; S Ben Redjeb; R Bercion; V Gautier; G Arlet
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

2.  Emergence and outbreaks of CTX-M beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains in a Tunisian hospital.

Authors:  Kelthoum Mamlouk; Ilhem Boutiba-Ben Boubaker; Valérie Gautier; Sophie Vimont; Bertrand Picard; Saida Ben Redjeb; Guillaume Arlet
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

3.  Nationwide study of the prevalence, characteristics, and molecular epidemiology of extended-spectrum-beta-lactamase-producing Enterobacteriaceae in France.

Authors:  Muriel Galas; Jean-Winoc Decousser; Nelly Breton; Thierry Godard; Pierre Yves Allouch; Patrick Pina
Journal:  Antimicrob Agents Chemother       Date:  2007-11-19       Impact factor: 5.191

4.  Increase in hospital-acquired bloodstream infections caused by extended spectrum beta-lactamase-producing Escherichia coli in a large French teaching hospital.

Authors:  L Drieux; F Brossier; O Duquesnoy; A Aubry; J Robert; W Sougakoff; M Lecso-Bornet; V Jarlier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-11-12       Impact factor: 3.267

5.  First description of Escherichia coli producing CTX-M-15- extended spectrum beta lactamase (ESBL) in out-patients from south eastern Nigeria.

Authors:  Ifeanyichukwu R Iroha; Charles O Esimone; Sandra Neumann; Lennart Marlinghaus; Miriam Korte; Florian Szabados; Sören Gatermann; Martin Kaase
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-07-23       Impact factor: 3.944

6.  Frequency of conjugative transfer of plasmid-encoded ISEcp1 - blaCTX-M-15 and aac(6')-lb-cr genes in Enterobacteriaceae at a tertiary care center in Lebanon - role of transferases.

Authors:  Mohamad Harajly; Marie-Therese Khairallah; John E Corkill; George F Araj; Ghassan M Matar
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-07-20       Impact factor: 3.944

7.  Different factors associated with CTX-M-producing ST131 and non-ST131 Escherichia coli clinical isolates.

Authors:  Marie-Hélène Nicolas-Chanoine; Jérôme Robert; Marie Vigan; Cédric Laouénan; Sylvain Brisse; France Mentré; Vincent Jarlier
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

8.  Prevalence of extended spectrum beta-lactamase production among uropathogens in south Mumbai and its antibiogram pattern.

Authors:  K Aruna; T Mobashshera
Journal:  EXCLI J       Date:  2012-07-06       Impact factor: 4.068

9.  Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15.

Authors:  Teresa M Coque; Angela Novais; Alessandra Carattoli; Laurent Poirel; Johann Pitout; Luísa Peixe; Fernando Baquero; Rafael Cantón; Patrice Nordmann
Journal:  Emerg Infect Dis       Date:  2008-02       Impact factor: 6.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.